Subcutaneous epcoritamab combined with rituximab plus lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: phase 1/2 trial update
Authors
Lorenzo, F.Sirpa, L.
Wahlin, B. E.
Marcel, N.
Christensen, J. H.
De, V. S.
Harald, H.
Linton, Kim M
Aqeel, A.
Wang, L. W.
Minh, D.
Brian, E.
David, B.
Affiliation
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York,New York, USA;Issue Date
2022